NAS:ARNA (USA) Also trade in: Germany UK

Arena Pharmaceuticals Inc

$ 57.23 1.91 (3.45%)
Volume: 645,857 Avg Vol (1m): 591,514
Market Cap $: 2.84 Bil Enterprise Value $: 1.78 Bil
P/E (TTM): 4.73 P/B: 2.35
Earnings Power Value -173.44
Net Current Asset Value 20.28
Tangible Book 24.26
Projected FCF 30.19
Median P/S Value 418.47
Graham Number 81.27
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

GuruFocus Articles Total 19
  • 1

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of The Blackstone Group L.P. (:BX), Arena Pharmaceuticals, Inc. (ARNA), Arrow Electronics, Inc. (:ARW), AdvanSix Inc. (:ASIX), KBR, Inc. (:KBR), and RPM International Inc. (:RPM), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links

0 Views    Marketwired    2019-03-26 12:00

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cameco Corporation (:CCJ), American Equity Investment Life Holding Company (:AEL), AG Mortgage Investment Trust, Inc. (:MITT), Arena Pharmaceuticals, Inc. (ARNA), Mimecast Limited (MIME), and Aldeyra Therapeutics, Inc. (ALDX), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to

0 Views    Marketwired    2019-01-30 13:04

NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cheniere Energy Partners, LP (:CQP), Arena Pharmaceuticals, Inc. (ARNA), Geron Corporation (GERN), Keysight Technologies Inc. (:KEYS), Grupo Aeroportuario del Centro Norte S.A.B. de C.V. (OMAB), and Casella Waste Systems, Inc. (CWST), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are

0 Views    Marketwired    2018-11-27 13:03

NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Meritor, Inc. (:MTOR), Fred's, Inc. (FRED), Arena Pharmaceuticals, Inc. (ARNA), AMERISAFE, Inc. (AMSF), Accelerate Diagnostics, Inc. (AXDX), and NextEra Energy, Inc. (:NEE), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

MTOR

0 Views    Marketwired    2018-10-15 16:01

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena Pharmaceuticals, Inc. (ARNA), Varian Medical Systems, Inc. (:VAR), SS&C Technologies Holdings, Inc. (SSNC), Globus Medical, Inc. (:GMED), Zynga Inc. (ZNGA), and Diamondrock Hospitality Company (:DRH), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the

0 Views    Marketwired    2018-08-14 16:02

NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Haemonetics Corporation (:HAE), Arena Pharmaceuticals, Inc. (ARNA), Xperi Corporation (XPER), MoneyGram International Inc. (MGI), Boot Barn Holdings, Inc. (:BOOT), and Green Dot Corporation (:GDOT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

HAE

0 Views    Marketwired    2018-05-15 16:00

Published On Retail Investor 360: Monday, 18 August 2014 23:08 Written by Doctor Hung V. Tran, MD, MS. Disclosure: We are long on MNKD and we do not have any financial relationship with any companies we cover.

360 catalyst key

  • 360 Biotech's contrarian thesis on the weight loss drugs developer published in 2013 was unwelcoming but turned out valid.
  • Stock promoters who were overly exuberant on Arena, Orexigen and/or VIVUS mislead investors. However, they now spin the fact to bash on these same companies despite a substantial drop in the share price.
  • The drastic share price declines widen
727 Views    hvt2107    2014-08-19 18:31
[img]http://pennyomega.com/img/arna.jpg[/img] [b] Arena Pharmaceuticals, Inc. (ARNA)[/b] [b]ARNA[/b] was initiated with a Buy and price target of $9.00 by brokerage firm WallachBeth. [b]ARNA[/b] closed at $5.46, up $0.35 (or +6.83%) . [img]http://pennyomega.com/img/arna_chart3.png[/img] [b]ARNA[/b] is a biopharmaceutical company focused on discovering, developing and commercializing novel-drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. [b]More about Arena Pharmaceuticals, Inc. (ARNA) at[/b] [url=http://www.arenapharm.com][b]www.arenapharm.com[/b][/url][b].[/b] ** [b][img]http://pennyomega.com/img/crwe_logo.jpg[/img] Crown Equity Holdings Inc. (CRWE)[/b] [b]CRWE[/b] is looking to deliver value for its stockholders in both the near and long term, and to improve the potential future growth for the company, [b]CRWE[/b] is targeting the
1274 Views    karnacua2    2013-11-16 19:11
According to [url=http://www.gurufocus.com/InsiderBuy.php]GuruFocus Insider Data[/url], the largest CFO sells during the past week were: Zynga Inc., Arena Pharmaceuticals Inc., Jack In The Box Inc., Tumi Holdings Inc. and Palo Alto Networks Inc. [b]Zynga Inc. (ZNGA): CFO Mark Vranesh Sold 125,000 Shares[/b] CFO [url=http://www.gurufocus.com/InsiderBuy.php?insider=Vranesh+Mark]Mark Vranesh[/url] sold 125,000 shares of ZNGA stock on April 1, 2013 at the average price of $3.26. Mark Vranesh owns at least 801,892 shares after this. The price of the stock has increased by 8.9% since. Zynga Inc. originally organized in April 2007 as a California limited liability company under the name Presidio Media LLC, and it
598 Views    Jimmy Xiao    2013-04-07 21:52
According to [url=http://www.gurufocus.com/InsiderBuy.php]GuruFocus Insider Data[/url], the largest CFO sells during the past week were: Qualcomm Inc., RailAmerica Inc., Arena Pharmaceuticals Inc., Actuant Corporation, Quest Diagnostics Inc., and Microsemi Corporation.

Qualcomm Inc. (QCOM): Executive Vice President and CFO William E. Keitel Sold 186,206 Shares

Executive Vice President and CFO, [url=http://www.gurufocus.com/InsiderBuy.php?insider=KEITEL+WILLIAM+E]William E. Keitel,[/url] sold 186,206 shares of QCOM stock on 10/01/2012 at the average price of $62.49. Keitel owns at least 9,194 shares after this. The price of the stock has increased by 0.26% since. Qualcomm Inc. develops and delivers innovative digital wireless communications products and services based on the company's CDMA digital
439 Views    Jimmy Xiao    2012-10-07 17:04
[b]Arena Pharmaceuticals[/b][b] (ARNA)[/b] is one of the three top contenders in what can be considered a weight loss drug battle royal. The Arena weight loss drug Lorcaserin is currently under FDA review. If approved it will be Arena’s chance to make some capital. The fact that Arena stock has risen 81% in the last three months leads me to think that many investors did not learn from their mistakes with Lorcaserin in the past. My cardinal rule in biotech investing is never invest money in a "promising" drug that does not have FDA approval. Drugs can so easily pass clinical
906 Views    StockCroc    2012-04-23 14:41
While obesity rates keep on rising both [url=http://www.obesityinamerica.org/statistics/index.cfm]in the U.S.[/url] and on a global level, many pharmaceutical companies find themselves in a neck-and-neck race in attempts to find a better cure that will manage to cease this epidemic. Today, one can find two types of U.S. FDA approved medication - medication for the short term treatment and medication for the long term treatment of [url=http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004552/]obesity[/url]. Despite the fact that obesity poses a large health concern and is considered to be one of the main causes of many disorders and diseases such as heart disease and [url=http://www.ia.ucsb.edu/pa/display.aspx?pkey=2547]diabetes[/url], the FDA has not
1372 Views    StockCroc    2012-04-22 19:56
[b]Vivus (VVUS)[/b] [url=http://www.businessweek.com/news/2012-04-09/vivus-weight-loss-drug-qnexa-gets-3-month-fda-review-extension]announced[/url] in early April that the FDA had deferred a decision on whether to approve the company's anti-obesity treatment, Qnexa, by a period of three months to mid-July. The extension was announced after the company, at the request of the FDA, submitted a risk evaluation and mitigation strategy. The advisers voted in late February in favor of the drug but raised concerns that the drug may have the potential to contribute to birth defects and heart disease. The strategy was based on discussions with the regulators in order to address these concerns. The company said that the extension
776 Views    InvestmentUnderground    2012-04-13 21:46
The companies presented in this article, much like [url= http://vatalyst.com/2012/01/05/6-coiled-spring-biotech-stocks-to-consider-in-2012/]others in the biotech sector[/url], are likely to give high returns over the next three years based off of their technological advancements and large markets they intend to serve. Sophisticated investors should note that, while investing in biotech stocks can [url=http://vatalyst.com/2012/01/17/can-these-biotechs-make-you-money-in-2012/]produce great returns[/url], it is risky because FDA approvals of drugs offer a binary outcome either the company makes it or it does not. Mannkind ([url=http://www.gurufocus.com/stock/mnkd]MNKD[/url]) The stock has been on a downward trend since January 2011 after the [url=http://www.reuters.com/article/2011/01/19/mannkind-idUSN1925178720110119]FDA[/url] failed to approve its new inhaled insulin device (Afrezza), and requested
1519 Views    Vatalyst.com    2012-02-08 23:16

Arena Pharmaceuticals Inc. (ARNA) filed Annual Report for the period ended 2010-12-31. Arena Pharmaceuticals Inc. has a market cap of $180.9 million; its shares were traded at around $1.49 with and P/S ratio of 17.4. Arena Pharmaceuticals Inc. had an annual average earning growth of 21% over the past 10 years.



Highlight of Business Operations:

Our most advanced drug candidate, lorcaserin, is intended for weight management, including weight loss and maintenance of weight loss. According to the Centers for Disease Control and Prevention, approximately one-third of US adults were obese in 2007-2008. Studies have shown that a weight loss of 5%

1136 Views    gurufocus    2011-03-15 22:24

Arena Pharmaceuticals Inc. (ARNA) filed Quarterly Report for the period ended 2010-09-30. Arena Pharmaceuticals Inc. has a market cap of $171.9 million; its shares were traded at around $1.53 with and P/S ratio of 16.5. Arena Pharmaceuticals Inc. had an annual average earning growth of 21% over the past 10 years.



Highlight of Business Operations:

Revenues. We recognized total revenues of $7.6 million for the three months ended September 30, 2010, compared to $2.6 million for the three months ended September 30, 2009. Our revenues for the three months ended September 30, 2010 included (i) $4.0 million of previously deferred non-cash

541 Views    gurufocus    2010-11-09 23:25

Arena Pharmaceuticals Inc. (ARNA) filed Quarterly Report for the period ended 2009-09-30. Arena Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena's most advanced product candidate, lorcaserin, is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. Arena Pharmaceuticals Inc. has

1016 Views    gurufocus    2009-11-10 00:19

Arena Pharmaceuticals Inc. (ARNA) filed Quarterly Report for the period ended 2009-06-30. Arena Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering developing and commercializing oral drugs in four major therapeutic areas: cardiovascular central nervous system inflammatory and metabolic diseases. Arena\'s most advanced product candidate lorcaserin is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena\'s broad pipeline of novel compounds targeting G protein-coupled receptors an important class of validated drug targets includes compounds being evaluated independently and with its partners Merck & Co. Inc. and Ortho-McNeil Pharmaceutical Inc. Arena Pharmaceuticals Inc. has

1107 Views    gurufocus    2009-08-08 03:18

Arena Pharmaceuticals Inc. (ARNA) filed Quarterly Report for the period ended 2009-03-31. Arena Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering developing and commercializing oral drugs in four major therapeutic areas: cardiovascular central nervous system inflammatory and metabolic diseases. Arena's most advanced product candidate lorcaserin is being investigated in a Phase three clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors an important class of validated drug targets includes compounds being evaluated independently and with its partners Merck & Co. Inc. and Ortho-McNeil Pharmaceutical Inc. Arena Pharmaceuticals Inc. has

1401 Views    gurufocus    2009-05-11 21:02

Headlines Total 200
  • 1
  • 2

2019-06-07 $56.7 (1.47%)
8:30am
2019-05-17 $54.01 (-3.24%)
8:45pm
2019-05-14 $54.85 (12.79%)
10:24am
2019-05-13 $48.63 (-6.14%)
8:00am
2019-05-10 $51.81 (1.11%)
7:45pm
4:44am
2019-05-09 $51.24 (3.47%)
8:03am
2019-05-02 $45.98 (4.07%)
8:26am
2019-03-28 $44.39 (0.36%)
8:30am
2019-03-07 $46.07 (0.37%)
1:46pm
2019-03-05 $48.76 (-0.08%)
2:27am
2019-02-28 $49.92 (1.53%)
9:16am
2019-02-27 $49.17 (-2.38%)
7:25am
2019-02-26 $50.37 (-0.4%)
9:01pm
2019-01-25 $44.57 (3.53%)
9:10am
2019-01-10 $43.97 (-0.02%)
2:12pm
2018-12-07 $40.55 (0.9%)
8:30am
2018-11-28 $40.56 (3.95%)
8:17pm
2018-11-23 $40.29 (1.46%)
11:58am
2018-11-21 $39.71 (1.02%)
10:21am
2018-11-20 $39.31 (-3.79%)
2:08pm
2018-11-19 $40.86 (-1.97%)
5:22pm
2018-11-16 $41.68 (5.39%)
8:11am
7:25am
6:02am
4:49am
2018-11-15 $39.55 (21.62%)
8:29pm
2018-11-09 $36.27 (-2.47%)
9:22am
7:17am
2018-11-08 $37.19 (-3.83%)
6:29am
2018-11-07 $38.67 (2.85%)
6:37am
2018-11-06 $37.6 (-0.05%)
8:30pm
2018-10-30 $34.48 (%)
9:33am
2018-10-05 $40.14 (-7.02%)
2:55pm
2:22pm
2018-10-04 $43.17 (-9.29%)
1:32am
2018-10-03 $47.59 (4.16%)
4:07pm
2018-09-26 $43.19 (-0.02%)
6:00am
2018-09-25 $43.2 (0.82%)
10:18am
2018-09-24 $42.85 (-2.06%)
10:50am
2018-09-05 $40.42 (3.38%)
8:12am
2018-08-29 $38 (0.42%)
9:22pm
2018-08-14 $36.89 (-0.11%)
11:02am
9:02am
$ARNA $CELG Bottom Celgene - seekingalpha.com
2018-08-13 $36.93 (0.63%)
10:26pm
2018-08-08 $37.65 (3.43%)
10:55pm
2018-08-07 $36.4 (-3.83%)
11:13pm
9:52am
2018-08-06 $37.85 (0.08%)
11:18pm
2018-07-27 $38.46 (-3.8%)
10:27am
2018-07-23 $43.78 (-0.09%)
1:11pm
2018-07-18 $43.88 (-1.55%)
9:03am
2018-07-17 $44.57 (1.27%)
9:11pm
2018-07-02 $44.55 (2.18%)
1:12pm
2018-06-20 $47.81 (-3.57%)
11:11am
2018-06-19 $49.58 (1.41%)
7:11am
5:55am
2018-06-13 $49.17 (0.47%)
9:16am
2018-06-07 $47.76 (-0.5%)
10:38am
8:05am
2018-05-31 $45.72 (3.35%)
4:14pm
2018-05-23 $46.4 (0.43%)
2:18pm
2018-05-20
3:21pm
2018-05-17 $47.29 (1.52%)
8:06pm
2018-05-15 $46.69 (2.35%)
8:30am
8:28am
2018-05-09 $41.99 (-0.07%)
9:38am
6:31am
2018-05-07 $42.67 (-1.04%)
7:30am
2018-05-05
6:46am
2018-05-02 $41.97 (5.58%)
1:45am
2018-05-01 $39.75 (-0.23%)
10:08am
9:20am
2018-04-27 $39.99 (-0.15%)
6:12am
2018-04-26 $40.05 (-0.82%)
10:30pm
11:09am
2018-04-21
7:16am
2018-04-13 $35.68 (0.99%)
8:57am
2018-03-28 $39.61 (-1.32%)
6:55pm
2018-03-26 $41.01 (-2.08%)
8:07am
2018-03-24
9:32am
1:55am
2018-03-23 $41.88 (1.7%)
6:00pm
2018-03-22 $41.18 (-6.41%)
4:58pm
7:41am
5:15am
2018-03-21 $44 (10.69%)
5:41pm
4:30pm
3:24pm
11:13am
9:39am
9:29am
8:00am
3:36am
2018-03-20 $39.75 (28.68%)
5:08pm
1:42pm
11:35am
10:43am
7:52am
7:00am
Total 200
  • 1
  • 2